Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Intracranial hemorrhage in critically ill patients hospitalized for COVID-19

Islam Fayed, Gnel Pivazyan, Anthony G. Conte, Jason Chang, Jeffrey C. Mai

MedStar Georgetown University Hospital, Department of Neurosurgery, 3800 Reservoir Road NW, 7PM, Washington, DC 20007, USA
MedStar Washington Hospital Center, Department of Neurosurgery, 110 Irving Street NW, Washington, DC 20010, USA
MedStar Washington Hospital Center, Department of Critical Care Medicine, 110 Irving Street NW, Washington, DC 20010, USA

Abstract

In this study, we report three cases of spontaneous intracranial hemorrhage in patients who were initially hospitalized at our tertiary care center in Washington, DC with symptoms of COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed in all three patients, who were critically ill, requiring intubation and ventilatory support. During their protracted hospitalizations, subsequent imaging disclosed intracranial hemorrhages, including intracerebral and subarachnoid hemorrhages, in the context of anticoagulation and coagulopathy. We believe this is related to the tropism of SARS-CoV-2 to the endothelial lining of the cerebral vasculature via their angiotensin-converting enzyme (ACE) II receptors. Given our findings, we advocate heightened vigilance for intracerebral hemorrhage events, and scanning when practicable, in COVID-19 patients who have prolonged ventilatory support and depressed neurologic examinations.

Keywords:
COVID-19
Coagulopathy
Endothelial injury
Intracerebral hemorrhage
Subarachnoid hemorrhage

We report three cases of spontaneous intracranial hemorrhage in patients who were initially hospitalized at our tertiary care center in Washington, DC with symptoms of COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed in all three patients, who were critically ill, requiring intubation and ventilatory support. During their protracted hospitalizations, subsequent imaging disclosed intracranial hemorrhages, including intracerebral and subarachnoid hemorrhages, in the context of anticoagulation and coagulopathy.

Our first patient was a 57-year-old woman with past medical history of hypertension, obesity, sleep apnea, and asthma who presented to our emergency department (ED) with shortness of breath and fever. After testing positive for SARS-CoV-2, she was initially admitted to the floor and subsequently escalated to the intensive care unit (ICU) and intubated for hypoxic respiratory failure. She developed acute renal insufficiency, requiring continuous venovenous hemofiltration under coverage of a heparin drip. Following two weeks of mechanical ventilation, a computed tomography (CT) scan of the head was performed given persistent encephalopathy, revealing a subacute lobar right frontal intracerebral hemorrhage (ICH) (Fig. 1A). No coagulation or platelet dyscrasias were uncovered. Repeat CT imaging was stable, and following negative PCR testing for SARS-CoV-2, she was able to undergo contrasted magnetic resonance imaging (MRI), which did not disclosed an underlying pathology for the original ICH and revealed interval development of ICH in the left frontal lobe, despite being off heparinization at that time (Fig. 1B and C). Interestingly, it also revealed significant inflammation of the sphenoid sinus – a putative mechanism for neuro-invasion by the virus (Fig. 1D). The patient was subsequently discharged to an acute rehabilitation facility one week later.

The second patient is a 54-year-old female with past medical history of hypertension, obesity, and bilateral mastectomy in 2016 for BRCA2 mutant breast cancer who presented to our ED with four days of myalgia and fever. After testing positive for SARS-CoV-2, she was discharged to home, but was admitted two days later with dyspnea and hypoxia necessitating mechanical ventilation. She continued to deteriorate, entering vasodilatory shock requiring vasopressors and epoprostenol treatment with prone positioning. She had a transient thrombocytopenia and was placed on a heparin drip for thromboembolic protection. At 24 h following cessation of heparin drip, at one week post-intubation, the patient developed dilated and non-reactive pupils and expired due to asystole four days later (Table 1).
The third patient is a 71-year-old gentleman with past medical history of hypertension, type II diabetes, chronic kidney disease, and B-cell lymphoma in remission who presented to the ED with acute onset shortness of breath and dizziness. After testing positive for SARS-CoV-2, the patient was admitted, progressing from a 15-liter supplement oxygen requirement to intubation, prone positioning, and vasopressor support within 5 days of admission. At two weeks post-intubation, persistent encephalopathy promoted a surveillance head CT, which disclosed a right occipital ICH with surrounding edema suggestive of hemorrhagic conversion of an infarct. While international normalized ratio (INR) and platelet counts were within normal range prior to the hemorrhage, they subsequently became profoundly hypercoagulable and thrombocytopenic afterwards, suspicious for disseminated intravascular coagulation (DIC). While the ICH remained stable on repeat imaging, the patient ultimately succumbed to multi-system organ failure one week later.

These cases support the predisposition of COVID-19 patients to the development of intracranial hemorrhage during critical illness. The pathophysiology is unclear, but the tropism of SARS-CoV-2 to the endothelial lining of the cerebral vasculature via their angiotensin-converting enzyme (ACE) II receptors, remains a possibility [1,2], and a recent pathology study The Lancet demonstrated the presence of virus particles within endothelial cells and an accumulation of inflammatory cells, leading to endothelial cell death [3]. Furthermore, a recent Italian review of animal studies suggests a higher neuro-invasive property of SARS-CoV-2 compared to other coronaviruses [4]. Zhou et al were able to detect SARS-CoV-2 RNA in human cerebrospinal fluid, and neurologic sequelae have been observed in an estimated 36% of COVID-19 patients [5–7]. Postmortem brain studies have also shown direct invasion of neurons and glial cells [8,9]. Several studies have suggested a pro-thrombotic state in these patients, possibly related to antiphospholipid antibodies, which may lead to ischemic complications related to occlusion of the cerebral vasculature [10–15]. Additionally, numerous reports of ICH in COVID-19 have begun to accumulate in the literature [16–20]. Collectively, these findings corroborate the possibility of direct cerebrovascular endothelial injury, vascular injury, and DIC leading to cerebral hemorrhagic events, exacerbated by concomitant anticoagulation therapy in two instances.

The ability to identify and treat these patients is hindered by the strict isolation and precautions mandated by COVID-19 infection. Given our findings, we advocate heightened vigilance for intracerebral hemorrhage events, and scanning when practicable, in COVID-19 patients which have prolonged ventilatory support and depressed neurologic examinations.

---

**Fig. 1.** A: Axial computed tomography (CT) of the head demonstrating a 3.5 × 3.4 × 3.2 cm acute intraparenchymal hematoma with inferior frontal midline shift. B,C: Axial magnetic resonance imaging (MRI) gradient echo (GRE) sequence demonstrating stable 3.2 cm right frontal intraparenchymal hematoma (C) with additional 0.6 cm left frontal intraparenchymal hematoma (C). D: Sagittal post-contrast T1 MRI with evidence of inflammation in the sphenoid sinus, a possible conduit for neuro-invasion by the virus. E, F: Axial (E) and coronal (F) non-contrast CT head demonstrating massive subarachnoid hemorrhage distributed throughout the basal cisterns with effacement of normal sulcal-gyri pattern. G,H: Axial (G) and sagittal (H) non-contrast CT head demonstrating a 2.2 × 2.2 cm intraparenchymal hemorrhage with surrounding hypodensity, suspicious for hemorrhagic transformation of a right-sided posterior cerebral artery (PCA) infarction.

I. Fayed, G. Pivazyan, A.G. Conte et al. Journal of Clinical Neuroscience 81 (2020) 192–195
Table 1
Clinical Characteristics of Three COVID+ Patients who Developed Intracranial Hemorrhages.

| Case 1 | Case 2 | Case 3 |
|--------|--------|--------|
| Age – years | 57 | 54 | 71 |
| Gender | Female | Female | Male |
| Medical History | Obesity, Sleep Apnea, Asthma | Hypertension, Bilateral Mastectomy (BRCA2 mutant breast cancer) | Hypertension, Type II Diabetes Mellitus, Chronic Kidney Disease, B-Cell Lymphoma (in Remission) |
| Relevant Medications | Aspirin 81 mg, Placebo vs Sarilumab, Epoprostenol | Desmopressin | N/A |
| Presenting COVID Symptoms | Shortness of Breath, Fever, Hypoxia | Body Aches, Fever, Dizziness | Shortness of Breath |
| Hospital Stay Prior to ICH – days | 20 | 8 | 20 |
| Duration of Intubation Prior to ICH – days | 18 | 8 | 15 |
| Prone Positioning | + | + | + |
| Other Critical Care Needs | Vasopressors, Continuous Veno-Venous Hemofiltration | Vasopressors | Vasopressors |
| Anticoagulation (Duration) | Heparin drip (6 days), Persistent Encephalopathy | Heparin drip (30 h), Fixed and Dilated Pupsils | N/A, Persistent Encephalopathy |
| Symptom Prompting Head Imaging | Right Frontal Lobar Intracerebral Hemorrhage | Diffuse Subarachnoid Hemorrhage | Right PCA distribution infarct with hemorrhagic conversion |
| Type and location of ICH | | | |
| Imaging Studies Performed | CT and MRI | CT and Nuclear Medicine Study | CT |
| Laboratory Values – At Presentation/At Time of ICH/Minimum-Maximum | | | |
| White Blood Cell Count – per mm3 | 10,700/24,800/8800–91,000 | 8300/17,300/5200–18,200 | 10,200/9300/5300–18,600 |
| Platelet Count – per mm3 | 200,000/181,000/159,00–506,000 | 135,000/213,000/17,000–137,000 | 207,000/354,000/64,000–360,000 |
| Prothrombin Time – seconds | 13.2/13.9/13.2–15.7 | 25.1/48.2/25.1–48.2 | 13.5/20.3/13.2–20.3 |
| Activated Partial-Thromboplastin Time – seconds | 2.0/20.8/20.8–40.9 | 1.0/1.1/1.0–1.2 | N/A/57.3/57.3–65.7 |
| International Normalized Ratio | 1.3/14.5/13.0–14.8 | 1.0/1.1/1.0–1.2 | 1.0/1.1/1.0–1.7 |
| Anti-Xa – IU/mL | N/A/0.23–1.0 | N/A/0.26/0.97–1.10 | N/A |
| Fibrinogen – mg/dL | N/A/638/382–1214 | 630/308/308–788 | 672/1276/672–1276 |
| D-dimer – mcg/mL | 1.06/14.08/1.06–18.63 | 0.52/13.79/0.52–20.00 | 1.44/9.55/1.44–9.88 |
| Outcome | Acute rehabilitation | Cerebral circulatory arrest confirmed by nuclear medicine study | Palliative extubation |

ICH: intracranial hemorrhage; CT: computed tomography; MRI: magnetic resonance imaging; PCA: posterior cerebral artery.

Acknowledgments
None.

Statement of ethics
This study did not require approval by our institution’s Institutional Review Board and did not require patient consent due to the retrospective nature of the analysis.

Disclosure statement
The authors certify that this manuscript is a unique submission and is not being considered for publication, in part or in full, with any other source in any medium. Each named author has substantially contributed to conducting the underlying research and drafting this manuscript. Additionally, to the best of our knowledge, the named authors have no conflict of interest, financial or otherwise.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References
[1] Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020. https://doi.org/10.1093/cvr/cvaa106
[2] Sharifi-Razavi A, Karimi N, Rouhani N. COVID-19 and intracerebral haemorrhage: causative or coincidental? New Microbes and New Infections 2020;35:.https://doi.org/10.1016/j.nmni.2020.100669
[3] Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395:1417–8. https://doi.org/10.1016/S0140-6736(20)30937-5
[4] Natoli S, Oliveira V, Calabresi P, Maia LF, Pisani A. Does SARS-Cov-2 invade the brain? Translational lessons from animal models. Eur J Neurol 2020.https://doi.org/10.1111/ene.14277
[5] Roe K. Explanation for COVID-19 infection neurological damage and reactivations. Transboundary Emerging Dis 2020. https://doi.org/10.1111/tbed.13594
[6] Zhou Z, Kang H, Li S, Zhao X. Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol 2020;267:2179–84. https://doi.org/10.1007/s00415-020-09599-7
[7] Tsai S-T, Lu M-K, San S, Tsai C-H. The neurologic manifestations of coronavirus disease 2019 pandemic: a systemic review. Front Neurol 2020;11. https://doi.org/10.3389/fneur.2020.00498.

[8] Md Noh MSF. COVID-19 and cerebral hemorrhage: proposed mechanisms. J Neuroradiol 2020. https://doi.org/10.1016/j.neurad.2020.05.007.

[9] Aghagoli G, Gallo Marin B, Katchur NJ, Chaves-Sell F, Asaad WF, Murphy SA. Neurological involvement in COVID-19 and potential mechanisms: a review. Neurolnt Care 2020. https://doi.org/10.1007/s12028-020-01049-4.

[10] Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020;382:. https://doi.org/10.1056/NEJMc2007575.

[11] Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. New Engl J Med 2020: e60. https://doi.org/10.1056/NEJMc2009787.

[12] Li Y, Li M, Wang M, Zhou Y, Chang J, Xian Y, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vascular Neurul 2020:svn-2020-000431. https://doi.org/10.1136/svn-2020-000431.

[13] Hernández-Fernández F, Valencia HS, Barbella-Aponte RA, Collado-Jiménez R, Ayo-Martín O, Barrena C, et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain 2020. https://doi.org/10.1093/brainawan2359.

[14] Reddy ST, Garg T, Shah C, Nascimento FA, Imran R, Kan P, et al. Cerebrovascular disease in patients with COVID-19: a review of the literature and case series. Case Rep Neurol 2020;199–209. https://doi.org/10.1159/000508958.

[15] Hanafi R, Roger P-A, Perin B, Kuchcinski C, Delevaux N, Gallyer F, et al. COVID-19 neurologic complication with CNS vasculitis-like pattern. Am J Neuroradiol 2020. https://doi.org/10.1177/027730742094851.

[16] Li J, Long X, Zhu C, Hu S, Lin Z, Li J, et al. A case of COVID-19 pneumonia with cerebral hemorrhage. Thromb Res 2020;193:22–4. https://doi.org/10.1016/j.thromres.2020.05.050.

[17] Krett JD, Jewett GA, Elton-Lacasse C, Fonseca K, Hahn C, Au S, et al. Hemorrhagic encephalopathy associated with COVID-19. J Neuroimmunol 2020;346:. https://doi.org/10.1016/j.jneuroim.2020.577326.

[18] Benger M, Williams O, Siddiqui J, Sztriha L. Intracerebral haemorrhage and COVID-19: clinical characteristics from a case series. Brain Behav Immun 2020;88:940–4. https://doi.org/10.1016/j.bbi.2020.06.035.

[19] García-García S, Cepeda S, Arrese I, Sarabia R. Letter: Hemorrhagic conditions affecting the central nervous system in COVID-19 patients. Neurosurgery 2020. https://doi.org/10.1093/neuros/nyaa252.

[20] Dong S, Liu P, Luo Y, Cui Y, Song L, Chen Y. Pathophysiology of SARS-CoV-2 infection in patients with intracerebral hemorrhage. Aging 2020;12:13791–802. https://doi.org/10.18632/aging.103511.